GlassScriptPhysician profile
Steven S Shayani
NPI 1306824008
$290,631.60
in general payments reported to CMS, 2019-2025
21 companies · $22K in 2025
The $22K reported for 2025 was more than what 97% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $60K · 2020: $37K · 2021: $40K · 2022: $50K · 2023: $36K · 2024: $46K · 2025: $22K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $95K · Food and Beverage: $4,855 · Travel and Lodging: $4,314.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $94,544.15 |
| Food and Beverage | $4,855.15 |
| Travel and Lodging | $4,314.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $188,970.87 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $43,211.22 | 2019-2025 | Jardiance |
| Amgen INC. | $35,097.42 | 2020-2025 | Repatha, Repatha |
| Sanofi-Aventis U.S. LLC | $12,635.39 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $4,506.98 | 2019 | |
| Pfizer INC. | $2,270.94 | 2019 | |
| Biotronik INC. | $1,677.42 | 2019-2025 | Amvia Edge, Acticor 7 Vr-T Dx, Biomonitor |
| Abbott Laboratories | $553.41 | 2019-2023 | Pressurewire, Cardiomems |
| Janssen Pharmaceuticals, INC | $543.33 | 2021-2024 | Xarelto |
| Medtronic Vascular, INC. | $318.55 | 2019 | |
| Boston Scientific Corporation | $157.71 | 2021-2025 | Cds - Mct/Cem Monitoring |
| Bayer Healthcare Pharmaceuticals INC. | $143.06 | 2025 | |
| Medtronic, INC. | $140.89 | 2025 | Symplicity G3 |
| Astellas Pharma US INC | $99.00 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $63.33 | 2024 | Camzyos, Eliquis |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $59.46 | 2025 | |
| Heartflow, INC. | $57.32 | 2024-2025 | |
| Terumo Medical Corporation | $56.79 | 2024 | Angio-Seal, Tr Band |
| Scpharmaceuticals INC. | $30.74 | 2024 | |
| Vivaquant INC, Dba Rhythm Express | $20.04 | 2025 | Rhythm Express |
| Intercept Pharmaceuticals, INC. | $17.73 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Shayani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.